Last reviewed · How we verify
NCT01563861
S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
trial testing RNA analysis in Lymphoma in 397 participants. Completed in 31 October 2013.
1 June 2008
Quick facts
| Lead sponsor | SWOG Cancer Research Network |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 397 |
| Start date | 15 September 1997 |
| Primary completion | 1 June 2008 |
| Estimated completion | 31 October 2013 |
Drugs / interventions tested
- RNA analysis
- gene expression analysis
- immunohistochemistry staining method
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Lymphoma — all drugs for Lymphoma →
Sponsor
SWOG Cancer Research Network
Who can join
18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies genes in samples from patients with limited and advanced diffuse large B-cell lymphoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.
Fan L, Li L, Zhou Y, Li J. · · 2017 · cited 6× · PMID 32300390 · DOI 10.14740/jh320w
Verify or expand the search:
- PubMed search for NCT01563861
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RNA analysis
Trials testing the same drug.
- NCT02984059 — Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease · completed
- NCT01489423 — Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sa · completed
- NCT01567722 — Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies · terminated
- NCT01505699 — Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia · completed
- NCT01267812 — Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transpla · Phase 2 · completed
Other recruiting trials for Lymphoma
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
- NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting
Other SWOG Cancer Research Network trials
Trials by the same sponsor.
- NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07278739 — Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams · NA · not yet recruiting
- NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
- NCT07018869 — Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01563861 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SWOG Cancer Research Network
- Last refreshed: 20 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01563861.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing